← Who reports today · Health Care
BDX · Q3 FY2026
Archived report (Q3 FY2026). Latest deep dive →
Net Income
$377M
down 34.3% y/y
Revenues
$4,983M
up 5.4% y/y
Operating Income
$663M
down 10.3% y/y
The quarter in brief
BD's revenue rose 5.4% to $4.98B, but operating income fell 10.3% to $663M and net income dropped 34.3% to $377M.
All figures in $M.
| Line item | Amount and change |
|---|---|
| Revenues | $4,983 · +5.4% |
| Cost of products sold | $2,668 · +7.1% |
| Selling and administrative expense | $1,261 · +8.4% |
| Research and development expense | $258 · +12.2% |
| Integration, restructuring and transaction expense | $89 · −7.3% |
| Other operating expense, net | $44 · +529% |
| Operating Income | $663 · −10.3% · 13.3% margin |
| Interest expense | $132 · −13.2% |
| Interest income | $4 · +0.0% |
| Other income (expense), net | $19 · vs −$22 |
| Income from Continuing Operations Before Income Taxes | $554 · −2.6% |
| Income tax provision | $102 · −13.6% · 18.4% effective rate |
| (Loss) Income from Discontinued Operations, Net of Tax | $74 · vs $123 |
| Net Income | $377 · −34.3% · $1.37/sh · 7.6% margin |
Verdict: BD's revenue rose 5.4% to $4.98B, but operating income fell 10.3% to $663M and net income dropped 34.3% to $377M.
Source and notation
Source: BDX press release, 8-K EX-99.1 of 08/06/2026 (SEC EDGAR).
Open as an image: BDX, Q3 FY2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “BDX Q3 FY2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/bdx/q3-fy2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/bdx/q3-fy2026"><img src="https://whoreportstoday.com/t/bdx/q3-fy2026/sankey.png" alt="BDX Q3 FY2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/bdx/q3-fy2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/bdx/q3-fy2026/sankey.png
<a href="https://whoreportstoday.com/t/bdx/q3-fy2026">BDX Q3 FY2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- GAAP diluted EPS from continuing operations was $1.64 and adjusted diluted EPS was $3.23, while year-to-date cash from continuing operations increased 33.3% to $2.1 billion.
- Operating income was $663M (−10.3% y/y), an operating margin of 13.3% vs 15.6% a year ago.
- Income tax of $102M implies an effective rate of 18.4% vs 20.7% a year ago.
- Diluted EPS was $1.37 vs $2.00 a year ago (−31.5%), while net income changed −34.3%.
What distorts the picture in this report and what to watch beyond the headlines.
BDX — a medical technology company that develops, makes and sells medical supplies, devices, laboratory equipment and diagnostic products to hospitals, physicians, clinical laboratories, researchers and drugmakers.
As of its fiscal 2025 report it had three worldwide segments: BD Medical, BD Life Sciences and BD Interventional. · Source: annual report (Form 10-K, SEC)
Heads-up
- net income fell 34% y/y in Q3 FY2026
Net income for Q3 FY2026: $377M, −34% y/y. In the report's figures: costs grew faster than revenue: other operating expense, net +529% y/y, research and development expense +12% y/y. Based on the Q3 FY2026 report.
The company's report ↗More reports: BIIB · Q3 2026 · BMY · Q3 2026 · BSX · Q3 2026 · CAH · Q1 FY2027 · CI · Q3 2026 · CNC · Q3 2026 · COO · Q3 FY2026 · COR · Q4 FY2026 · CRL · Q3 2026 · CVS · Q3 2026 · all reports